More News: Novel Therapeutic Target in Chronic Lymphocytic Leukemia Cells Identified
View web version
Breaking News
Phase 3 Motesanib Trial for East Asian Patients With NSCLC Misses Primary Endpoint
For this randomized phase 3 study, patients were assigned to motesanib plus paclitaxel and carboplatin (197 patients) or to placebo plus paclitaxel and carboplatin (204 patients).
More News
First-line Cabozantinib Improves PFS in Clear Cell Renal Cell Carcinoma
Nintedanib Prolongs Progression-free Survival in Mesothelioma
Rucaparib May Prolong PFS in Ovarian Cancer Responsive to Platinum Chemotherapy
Fact Sheet
beta-Carotene and Cancer

Want to receive emails specific to your profession and specialty? Click here to complete your profile.

If you were sent this by a colleague and wish to subscribe to Weekly highlights, please click here.

To unsubscribe from the Weekly Highlights click here.
To manage your entire Cancer Therapy Advisor profile login to your account.

You are subscribed as: %%EMAIL%%

To contact Haymarket Media for general questions or unsubscribe problems, please reply to this email.

All Cancer Therapy Advisor newsletters are sent from the domain "". When configuring e-mail or spam filter rules, please use this domain name.

© 2017 Haymarket Media Inc
275 7th Avenue, 10th Floor
New York, NY 10001